Research progress in potential urinary markers for the early detection, diagnosis and follow-up of human bladder cancer

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 1723-1726

  Wang, Hai Feng ^a   Wang, Jian Song ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Bladder cancer; Detection; Diagnosis; Follow up; Tumor marker

Indexed keywords

TUMOR MARKER;

BLADDER TUMOR; EARLY DIAGNOSIS; HUMAN; MEDICAL RESEARCH; REVIEW; URINE;

BIOMEDICAL RESEARCH; EARLY DIAGNOSIS; HUMANS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84872681342     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.1723     Document Type: Article

References (25)

1. Akhidova EV, Volkova TD, Koroev DO, et al (2010). Antibodies to synthetic peptides for the detection of survivin in tumor tissues. Bioorg Khim, 36,178-86.
2. Arora VK, Sarungbam J, Bhatia A, et al (2010). Usefulness of NMP22 as an adjunct to a typical urine cytology and lowgrade urothelial carcinoma. Diagn Cytopathol, 38, 788-90.
3. Casadio V, Bravaccini S, Gunelli R, et al (2009). Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients. Int J Biol Markers, 24, 253-7.
4. Choi HS, Lee SI, Kim DJ, et al (2010). Usefulness of the NMP22BladderChek Test for Screening and Follow-up of Bladder Cancer. Korean J Urol, 51, 88-93.
5. Eissa S, Swellam M, Shehata H, et al (2010). Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer. J Urol, 183, 493-8.
6. Gradilone A, Petracca A, Nicolazzo C, et al (2010). Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer. BJU Int, 106, 710-5.
7. Gravas S, Bosinakou I, Kehayas P et al (2004). Urinary basic fibroblast growth factor in bladder cancer patients. Histopathological correlation and clinical potential. Urol Int, 73, 173-7.
8. Guo B, Che T, Shi B, et al (2011). Screening and identification of specific markers for bladder transitional cell carcinoma from urine urothelial cells with suppressive subtractive hybridization and cDNA microarray. Can Urol Assoc J, 5, E129-37.
9. He XF, Wen DG, Hou JQ, et al (2009). Expressions of survivin and the splice variants survivin-2B and survivin-DeltaEx3 in bladder cancer and their clinical significance. AI ZHENG, 28, 1209-13.
10. Hwang EC, Choi HS, Jung SI, et al (2011). Use of the NMP22 BladderChek test in the diagnosis and follow-up of urothelial cancer: a cross-sectional study. Urology, 77, 154-9.
11. Iwabuchi I, Mori K, Yamamoto H, et al (2010). Significance of a simple assay of urine telomerase activity for the detection of bladder cancer. Hinyokika Kiyo, 56, 551-7.
12. Jovanovic M, Hadzi-Djokic J, Dzamic Z, et al (2007). Evaluation of the Bard BTA-test in the diagnosis of upper urinary tract tumours. Acta Chir Iugosl, 54, 19-24.
13. Kehinde EO, Al-Mulla F, Kapila K, et al (2011). Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer. Scand J Urol Nephrol, 45, 113-21.
14. Kramer MW, Golshani R, Merseburger AS, et al (2010). HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol, 57, 86-93.
15. Kundal VK, Pandith AA, Hamid A, et al (2010). Role of NMP22 bladder check test in early detection of bladder cancer with recurrence. Asian Pac J Cancer Prev, 11, 1279-82.
16. Lai Y, Ye J, Chen J, et al (2010). UPK3A: a promising novel urinary marker for the detection of bladder cancer. Urology, 76, 514. e6-11.
17. Lau P, Chin JL, Pautler S, et al (2009). NMP22 is predictive of recurrence in high-risk superficial bladder cancer patients. Can Urol Assoc J, 3, 454-8.
18. Marzioni D, Lorenzi T, Mazzucchelli R, et al (2009). Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. Int J Immunopathol Pharmacol, 22, 627-38.
19. Proctor I, Stoeber K, Williams GH (2010). Biomarkers in bladder cancer. Histopathology, 57, 1-13.
20. Raitanen MP (2008). The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies. World J Urol, 26, 45-50.
21. Shariat SF, Karakiewicz PI, Godoy G, et al (2009). Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res, 15, 7012-9.
22. Shariat SF, Savage C, Chromecki TF, et al (2011). Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis. Cance, 13, 2892-7.
23. Van Le TS, Myers J, Konety BR, et al (2004). Functional characterization of the bladder cancer marker, BLCA-4. Clin Cancer Res, 10, 1384-91.
24. Xue Y, Li L, Zhang D, et al (2010). Telomerase suppression initiates PML-dependent p53 activation to inhibit bladder cancer cell growth. Oncol Rep, 24, 1551-9.
25. Yang D, Song X, Zhang J, et al (2010). Therapeutic potential of siRNA-mediated combined knockdown of the IAP genes (Livin, XIAP, and Survivin) on human bladder cancer T24 cells. Acta Biochim Biophys Sin, 42, 137-44.